8-K: Tempus AI Announces Strong Preliminary Results for Q4 and Full Year 2024, Exceeding Revenue Guidance

Tempus AI reported preliminary unaudited results for the fourth quarter and full year 2024, showing significant revenue growth and exceeding expectations for both revenue and adjusted EBITDA.

Summary

• Tempus AI has released preliminary, unaudited financial results for the fourth quarter and full year 2024.
• Full year revenue is approximately $693 million, representing a 30% year-over-year growth.
• Fourth quarter revenue reached approximately $200 million, a 35% increase year-over-year.
• The company saw continued improvement in adjusted EBITDA compared to the prior year.
• Genomics revenue is expected to grow by approximately 30% in Q4, and data and services revenue is expected to grow by approximately 45%.
• Tempus expects to deliver approximately 99% of its revenue guidance and 100% of its adjusted EBITDA guidance for 2024.
• The company's core businesses showed strength throughout the year, despite some softness in CRO revenues.
• These results are preliminary and subject to change as Tempus completes its year-end close procedures.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, exceeding guidance, and improvements in adjusted EBITDA. However, the preliminary nature of the results and the mention of potential material differences temper the overall optimism.

Positives

• The company experienced strong revenue growth for both the full year and the fourth quarter.
• Adjusted EBITDA improved year-over-year and sequentially in the fourth quarter.
• The company's core businesses, genomics and data services, showed strong growth.
• Tempus is on track to meet or exceed its financial guidance for 2024.
• The company is making progress on its Ambry acquisition.

Negatives

• There was some softness in CRO revenues.
• The financial results are preliminary and unaudited, and may change.
• Final results could differ materially from the estimates presented.

Risks

• The preliminary financial results are subject to change as the company completes its year-end close procedures.
• Final results may differ materially from the estimates provided.
• The company faces risks related to competition, new market entrants, and compliance with evolving regulations, especially in the AI space.
• There are risks associated with the ability to consummate the Ambry acquisition and realize its expected benefits.
• The company is subject to risks related to macroeconomic conditions, climate change, and health epidemics.

Future Outlook

Tempus plans to report its complete fourth quarter and full year 2024 financial results during its first earnings call of 2025. The company also anticipates the closing of the Ambry acquisition.

Management Comments

• Eric Lefkofsky, Founder and CEO of Tempus, stated that the company concluded 2024 with continued strength in its core businesses.
• He noted that genomics revenue is expected to grow at ~30% in Q4 and data and services revenue is expected to grow at ~45%.

Industry Context

This announcement highlights the growing importance of AI and data-driven approaches in precision medicine. Tempus's strong revenue growth and focus on genomics and data services position it well within the competitive landscape of healthcare technology companies.

Comparison to Industry Standards

• While specific competitor data is not provided in this document, Tempus's 30% full year revenue growth and 35% Q4 growth are strong indicators of performance in the healthcare technology sector.
• Companies like Exact Sciences (EXAS) and Guardant Health (GH) are also focused on genomics and precision medicine, and their growth rates and financial metrics would be relevant for comparison when available.
• The adjusted EBITDA improvement is a positive sign, as many growth-stage companies in this sector are focused on achieving profitability.

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue growth and exceeding of guidance.
• Employees may be encouraged by the company's performance and future prospects.
• Customers and partners may see the results as a sign of the company's continued strength and reliability.

Next Steps

• Tempus will complete its year-end close and review procedures.
• The company plans to report its complete fourth quarter and full year 2024 financial results during its first earnings call of 2025.
• The company will continue to work towards closing the Ambry acquisition.

Key Dates

Keywords

Tempus AI, Precision Medicine, Artificial Intelligence, Genomics, Data Services, Financial Results, Revenue Growth, Adjusted EBITDA, Healthcare Technology, Ambry Acquisition